Jasmin B Kuemmerle-Deschner

Summary

Country: Germany

Publications

  1. ncbi [Cryopyrin-associated periodic syndrome]
    J B Kümmerle-Deschner
    Klinik fur Kinder und Jugendmedizin, Abteilung für pädiatrische Rheumatologie, Autoinflammation Reference Center Tübingen, Universitatsklinikum Tubingen, Hoppe Seyler Str 1, 72076, Tubingen, Deutschland
    Z Rheumatol 71:199-208. 2012
  2. ncbi NLRP3 E311K mutation in a large family with Muckle-Wells syndrome--description of a heterogeneous phenotype and response to treatment
    Jasmin B Kuemmerle-Deschner
    Division of Pediatric Rheumatology, Dept, of Pediatrics, University Hospital Tubingen, Hoppe Seyler Straße 1, 72076 Tuebingen, Germany
    Arthritis Res Ther 13:R196. 2011
  3. ncbi Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis
    Jasmin B Kuemmerle-Deschner
    Division of Pediatric Rheumatology, University Children s Hospital Tubingen, Tubingen, Germany
    Rheumatol Int 28:153-6. 2007
  4. ncbi Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement
    J B Kuemmerle-Deschner
    Division of Paediatric Rheumatology, University Children s Hospital Tuebingen, Germany
    Rheumatology (Oxford) 47:1051-3. 2008
  5. ncbi Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
    Jasmin B Kuemmerle-Deschner
    Division of Pediatric Rheumatology, Department of Pediatrics, University Children s Hospital Tuebingen, Hoppe Seyler Strasse 1, 72076 Tubingen, Tuebingen, Germany
    Arthritis Res Ther 13:R34. 2011
  6. ncbi Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome
    Jasmin B Kuemmerle-Deschner
    University Hospital Tubingen, Tubingen, Germany
    Arthritis Rheum 63:840-9. 2011
  7. ncbi Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
    Jasmin B Kuemmerle-Deschner
    Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tubingen, Germany
    Ann Rheum Dis 70:2095-102. 2011
  8. ncbi Hearing loss in Muckle-Wells syndrome
    Jasmin B Kuemmerle-Deschner
    University Hospital Tuebingen, Tuebingen, Germany
    Arthritis Rheum 65:824-31. 2013
  9. ncbi Progressive familial hearing loss in Muckle-Wells syndrome
    Assen Koitschev
    Department of Otorhinolaryngology, Klinikum Stuttgart, University Hospital Tubingen, Germany
    Acta Otolaryngol 132:756-62. 2012

Collaborators

Detail Information

Publications9

  1. ncbi [Cryopyrin-associated periodic syndrome]
    J B Kümmerle-Deschner
    Klinik fur Kinder und Jugendmedizin, Abteilung für pädiatrische Rheumatologie, Autoinflammation Reference Center Tübingen, Universitatsklinikum Tubingen, Hoppe Seyler Str 1, 72076, Tubingen, Deutschland
    Z Rheumatol 71:199-208. 2012
    ..To prevent severe and possible life-threatening disease sequelae, early and correct diagnosis and immediate initiation of therapy are mandatory...
  2. ncbi NLRP3 E311K mutation in a large family with Muckle-Wells syndrome--description of a heterogeneous phenotype and response to treatment
    Jasmin B Kuemmerle-Deschner
    Division of Pediatric Rheumatology, Dept, of Pediatrics, University Hospital Tubingen, Hoppe Seyler Straße 1, 72076 Tuebingen, Germany
    Arthritis Res Ther 13:R196. 2011
    ..The NLRP3/CIAS1 E311K mutation caused a heterogeneous phenotype of MWS in a large family. This study analyzes the clinical spectrum, patterns of inflammatory parameters and reports on response to treatment...
  3. ncbi Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis
    Jasmin B Kuemmerle-Deschner
    Division of Pediatric Rheumatology, University Children s Hospital Tubingen, Tubingen, Germany
    Rheumatol Int 28:153-6. 2007
    ..At last observation 10/12 patients achieved an ACR-JRA 30 and 8/12 achieved an ACR-JRA70 response. These data indicate that once weekly application of etanercept is safe and efficacous in children...
  4. ncbi Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement
    J B Kuemmerle-Deschner
    Division of Paediatric Rheumatology, University Children s Hospital Tuebingen, Germany
    Rheumatology (Oxford) 47:1051-3. 2008
    ..To report the successful treatment with recombinant human IFN- alpha 2a (rhIFN-alpha2a) in two male adolescents suffering from severe treatment-resistant Behçet's disease (BD) with central nervous system (CNS) involvement...
  5. ncbi Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS)
    Jasmin B Kuemmerle-Deschner
    Division of Pediatric Rheumatology, Department of Pediatrics, University Children s Hospital Tuebingen, Hoppe Seyler Strasse 1, 72076 Tubingen, Tuebingen, Germany
    Arthritis Res Ther 13:R34. 2011
    ..Canakinumab, a fully human anti-IL-1β antibody, produces sustained selective inhibition of IL-1β. This study was conducted to assess the efficacy, safety, and pharmacokinetics of canakinumab in the treatment of pediatric CAPS patients...
  6. ncbi Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome
    Jasmin B Kuemmerle-Deschner
    University Hospital Tubingen, Tubingen, Germany
    Arthritis Rheum 63:840-9. 2011
    ..The recombinant IL-1 receptor antagonist anakinra blocks the biologic activity of IL-1. The aim of this study was to determine the short- and long-term efficacy and safety of anakinra therapy in children and adults with severe MWS...
  7. ncbi Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
    Jasmin B Kuemmerle-Deschner
    Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tubingen, Germany
    Ann Rheum Dis 70:2095-102. 2011
    ..Longer-term effects of prolonged selective interleukin-1β blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date...
  8. ncbi Hearing loss in Muckle-Wells syndrome
    Jasmin B Kuemmerle-Deschner
    University Hospital Tuebingen, Tuebingen, Germany
    Arthritis Rheum 65:824-31. 2013
    ..The aims of this study were to determine the otologic characteristics of MWS, define trajectories of hearing loss, and explore the association with distinct NLRP3 genotypes...
  9. ncbi Progressive familial hearing loss in Muckle-Wells syndrome
    Assen Koitschev
    Department of Otorhinolaryngology, Klinikum Stuttgart, University Hospital Tubingen, Germany
    Acta Otolaryngol 132:756-62. 2012
    ..The design of further clinical trials should focus on hearing in order to document the long-term effect of anti-interleukin (IL)-1 drugs on hearing preservation...